PMID- 19372057
OWN - NLM
STAT- MEDLINE
DCOM- 20110505
LR  - 20110103
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 29
IP  - 1
DP  - 2011 Jan-Feb
TI  - Sex-specific hormone receptors in urothelial carcinomas of the human urinary 
      bladder: a comparative analysis of clinicopathological features and survival 
      outcomes according to receptor expression.
PG  - 43-51
LID - 10.1016/j.urolonc.2009.01.033 [doi]
AB  - OBJECTIVES: To investigate the expression of sex-specific hormone receptors in 
      normal bladder urothelium and urothelial carcinomas (UCs) of the bladder, and to 
      analyze clinicopathological features and survival outcomes according to receptor 
      expression. METHODS: We evaluated the clinical data and tumor specimens of 139 
      patients with bladder cancer (BC). In addition, 72 samples of normal urothelium 
      were included. Immunohistochemistry was performed using streptavidin-biotin 
      peroxidase method, a monoclonal androgen receptor (AR), and an estrogen 
      receptor-beta (ERbeta) antibody on paraffin-embedded tissue sections. Expression levels 
      of each receptor were assessed by evaluating 500 tumor cells for each case and 
      the percentage of positively-stained nuclei was recorded. RESULTS: None of the 58 
      male control cases showed any AR and ERbeta expression. Five (35, 71%) of the 14 
      female control cases expressed ERbeta. Of the 139 patients with UCs, 71 (51, 07%) 
      expressed AR (62 male vs. 9 female; P = 0.413) and 44 (31, 65%) (39 male vs. 5 
      female; P = 0.402) showed ERbeta expression (P < 0.001). No significant relationship 
      was found between ERbeta expression levels and tumor grades, and stages (P = 0.441; 
      P = 0.247). AR expression was significantly lower in T2-tumors (21%) than in 
      Ta-tumors (60%) and T1-tumors (60%) (P < 0.001). It was significantly higher in 
      low-grade papillary UCs (64%) compared with high-grade papillary UCs (44%) and 
      infiltrative high-grade UCs (17%) (P = 0.039; P < 0.001). Data of 79 patients 
      with noninvasive BC were eligible to present, with a median 29 months follow-up. 
      AR expression level did not influence recurrence-free survival (RFS) and 
      progression-free survival (PFS) (P = 0.095; P = 0.110). No significant 
      association was found between ERbeta expression level and RFS (P = 0.293). PFS in 
      patients with lower ERbeta-expressing tumors was significantly better than that in 
      patients with higher ERbeta-expressing tumors (P = 0.035). Multivariate analysis 
      confirmed this significant influence on PFS (P = 0.025). CONCLUSIONS: Although 
      ERbeta expression had no impact on histopathological tumor characteristics, decrease 
      in its expression may be associated with better PFS rates in patients with 
      noninvasive BC. Conversely, loss of AR expression was associated with higher 
      grade UCs and invasive UCs, but had no prognostic effect on survival. Finally, 
      sex-specific hormone receptors alone cannot be responsible for gender differences 
      in BC rates because they were expressed in similar rates in both sexes.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Tuygun, Can
AU  - Tuygun C
AD  - Department of Urology, Ministry of Health Yildirim Beyazit Diskapi Educational 
      and Research Hospital, Ankara, Turkey. tuyguncan@yahoo.com
FAU - Kankaya, Duygu
AU  - Kankaya D
FAU - Imamoglu, Abdurrahim
AU  - Imamoglu A
FAU - Sertcelik, Ayse
AU  - Sertcelik A
FAU - Zengin, Kursad
AU  - Zengin K
FAU - Oktay, Murat
AU  - Oktay M
FAU - Sertcelik, Nurettin
AU  - Sertcelik N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090416
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (AR protein, human)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Receptors, Androgen)
SB  - IM
MH  - Carcinoma, Transitional Cell/*metabolism/pathology
MH  - Case-Control Studies
MH  - Estrogen Receptor beta/*metabolism
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptors, Androgen/*metabolism
MH  - Survival Rate
MH  - Urinary Bladder/*metabolism
MH  - Urinary Bladder Neoplasms/*metabolism/pathology
EDAT- 2009/04/18 09:00
MHDA- 2011/05/06 06:00
CRDT- 2009/04/18 09:00
PHST- 2008/11/25 00:00 [received]
PHST- 2009/01/25 00:00 [revised]
PHST- 2009/01/27 00:00 [accepted]
PHST- 2009/04/18 09:00 [entrez]
PHST- 2009/04/18 09:00 [pubmed]
PHST- 2011/05/06 06:00 [medline]
AID - S1078-1439(09)00035-0 [pii]
AID - 10.1016/j.urolonc.2009.01.033 [doi]
PST - ppublish
SO  - Urol Oncol. 2011 Jan-Feb;29(1):43-51. doi: 10.1016/j.urolonc.2009.01.033. Epub 
      2009 Apr 16.